New oral anticoagulant-induced bleeding: clinical presentation and management.

Published

Other Article (Review)

Bleeding is a significant complication of anticoagulant therapy. With the emergence of new oral anticoagulants (NOACs; ie, direct factor IIa or Xa inhibitors), this risk is further compounded by the lack of validated reversal strategies for these agents. Emerging postmarketing evidence suggests that the bleeding risks are in line with results observed in head-to-head clinical trials of NOACs versus traditional anticoagulants. Several guidelines have recommended the use of hemostatic agents for NOAC reversal in patients with life-threatening bleeding. Ultimately, adequately powered studies will be crucial for full assessment of the effectiveness and safety of any proposed reversal strategies.

Full Text

Duke Authors

Cited Authors

  • Levy, JH; Levi, M

Published Date

  • September 2014

Published In

Volume / Issue

  • 34 / 3

Start / End Page

  • 575 - 586

PubMed ID

  • 25168943

Pubmed Central ID

  • 25168943

Electronic International Standard Serial Number (EISSN)

  • 1557-9832

Digital Object Identifier (DOI)

  • 10.1016/j.cll.2014.06.004

Language

  • eng

Conference Location

  • United States